Literature DB >> 35228392

ETV6 Regulates Hemin-Induced Erythroid Differentiation of K562 Cells through Mediating the Raf/MEK/ERK Pathway.

Zhaopeng Li1, Ming-Zhong Sun2, Xinxin Lv2, Chunmei Guo2, Shuqing Liu1.   

Abstract

As a member of transcription factor E-Twenty Six (ETS) family, ETS variant 6 (ETV6) plays significant role in hematopoiesis and embryonic development. ETV6 dysexpression also involved in the occurrence, development and progression of cancers and leukemia. In current work, we hypothesized that ETV6 plays a role in erythroid differentiation of chronic myeloid leukemia (CML). We found the protein expression level of ETV6 was significantly upregulated during hemin-induced erythroid differentiation of K562 cells. Moreover, overexpression of ETV6 inhibited erythroid differentiation in hemin-induced K562 cells with decreased numbers of benzidine-positive cells and decreased expression levels of erythroid differentiation specific markers glycophorin (GPA), CD71, hemoglobin A (HBA), α-globin, γ-globin and ε-globin. Conversely, ETV6 knockdown promoted erythroid differentiation in hemin-induced K562 cells. Furthermore, ETV6 expression level slightly positively with the proliferation capacity of K562 cells treated with hemin. Mechanistically, ETV6 overexpression inhibited fibrosarcoma/mitogen activated extracellular signal-regulated kinase/extracellular regulated protein kinase (Raf/MEK/ERK) pathway, ETV6 knockdown activated the Raf/MEK/ERK pathway. Collectively, the current work demonstrates that ETV6 plays an inhibitory role in the regulation of K562 cell erythroid differentiation via Raf/MEK/ERK pathway, it would be a potentially therapeutic target for dyserythropoiesis.

Entities:  

Keywords:  E-Twenty Six variant 6; chronic myeloid leukemia; erythroid differentiation; extracellular regulated protein kinase (ERK) pathway; mitogen activated extracellular signal-regulated kinase (MEK); rapidly accelerated fibrosarcoma (Raf)

Mesh:

Substances:

Year:  2022        PMID: 35228392     DOI: 10.1248/bpb.b21-00632

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  LRF Promotes Indirectly Advantageous Chromatin Conformation via BGLT3-lncRNA Expression and Switch from Fetal to Adult Hemoglobin.

Authors:  Vasiliki Chondrou; Athanasios-Nasir Shaukat; Georgios Psarias; Katerina Athanasopoulou; Evanthia Iliopoulou; Ariadne Damanaki; Constantinos Stathopoulos; Argyro Sgourou
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

2.  Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate.

Authors:  Ismail Siti Mariam; Ramli Norhidayah; Abu Bakar Zulaikha; Mohd Yunus Nazihah; Hassan Rosline; Ghazali Anis Kausar; Sulong Sarina; Husin Azlan; Ravindran Ankathil
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.